Mordor Intelligence has published a new report on the Gene Therapy Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
The gene therapy market is poised for significant growth, with projections indicating an increase from USD 9.19 billion in 2025 to USD 31.58 billion by 2030, reflecting a compound annual growth rate (CAGR) of approximately 28%. This expansion is driven by technological advancements and a rising prevalence of chronic diseases. Cell and gene therapies represent a transformative approach in medical science, offering potential cures for diseases previously considered incurable. By modifying genetic material or utilizing living cells, these therapies aim to treat, prevent, or potentially cure various conditions, including genetic disorders, cancers, and chronic diseases. The market’s rapid expansion is fueled by significant investments in research and development, favorable regulatory approvals, and a growing demand for personalized medicine.
Key Trends Driving Market Growth
- Regulatory Milestones and Approvals
The landscape of cell and gene therapy has evolved with significant regulatory advancements. A notable milestone was achieved in August 2022 when the U.S. Food and Drug Administration (FDA) approved Zynteglo (betibeglogene autotemcel), marking the first cell-based genetic therapy for treating beta-thalassemia in both adult and pediatric patients. Such approvals set important precedents for future therapies, particularly in addressing rare genetic disorders.
- Rising Prevalence of Chronic Diseases
The increasing global burden of chronic diseases, such as cancer and genetic disorders, has heightened the demand for innovative treatments. For instance, the World Health Organization anticipates over 35 million new cancer cases by 2024, representing a 77% rise from 2022 figures. This surge underscores the critical need for advanced therapies, thereby driving the cell and gene therapy market.
- Strategic Collaborations and Investments
Collaborations between biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) are enhancing market opportunities. For example, in May 2023, AGC Biologics launched its BravoAAV and ProntoLVV viral vector platforms, offering accelerated vector development and manufacturing for cell and gene therapy programs. Such partnerships are pivotal in advancing therapeutic development and commercialization.
Report Overview: https://www.mordorintelligence.com/industry-reports/gene-therapy-market
Market Segmentation
The cell and gene therapy market is segmented based on therapy type, indication, and geography:
- By Therapy Type
- Cell Therapy: Involves the administration of live cells to replace or repair damaged tissue, with applications in treating various diseases.
- Gene Therapy: Entails the introduction, removal, or alteration of genetic material within a patient’s cells to treat disease, utilizing vectors like viral or non-viral vectors.
- By Indication
- Oncology: Treatments targeting various cancers, including CAR-T cell therapies.
- Cardiovascular Diseases: Therapies aimed at repairing heart tissue and improving cardiac function.
- Infectious Diseases: Innovations addressing diseases such as HIV and hepatitis.
- Genetic Disorders: Therapies targeting conditions like cystic fibrosis and muscular dystrophy.
- Neurological Disorders: Treatments for diseases such as Parkinson’s and Alzheimer’s.
- By Geography
- North America: Holds the largest market share, driven by advanced healthcare infrastructure and significant R&D activities.
- Europe: Notable for collaborative research initiatives and supportive regulatory frameworks.
- Asia-Pacific: Expected to experience the highest growth rate, attributed to increasing investments in biotechnology and expanding healthcare infrastructure.
Get a Customized Report Tailored to Your Requirements. – https://www.mordorintelligence.com/market-analysis/gene-therapy
Key Players in the Market
The cell and gene therapy market features a mix of established pharmaceutical giants and specialized biotechnology firms. Prominent companies include:
- Novartis AG: A leader in CAR-T cell therapies, notably with its Kymriah treatment for certain types of lymphoma and leukemia.
- Gilead Sciences, Inc.: Known for Yescarta, a CAR-T therapy for specific blood cancers.
- Bluebird Bio, Inc.: Focuses on gene therapies for severe genetic diseases, including beta-thalassemia and sickle cell disease.
- Bristol-Myers Squibb Company: Offers Breyanzi, a CAR-T therapy approved for certain types of large B-cell lymphoma.
- F. Hoffmann-La Roche Ltd: Engaged in developing gene therapies across various therapeutic areas.
These companies are at the forefront of developing and commercializing innovative therapies, contributing significantly to market growth.
Conclusion
The cell and gene therapy market is on a trajectory of remarkable growth, propelled by technological advancements, increasing disease prevalence, and strategic industry collaborations. As research progresses and more therapies receive regulatory approval, these treatments are expected to become integral components of modern medical practice, offering hope for conditions that were once deemed incurable.
Industry Related Reports
CAR T-Cell Therapy Market: The report provides an in-depth analysis of global CAR T-cell therapy manufacturers and is categorized based on type, application, end users, and geography. The types covered include Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and others. Applications are segmented into leukemia, lymphoma, multiple myeloma, autoimmune disorders, and other medical uses. End users encompass hospitals and cancer care treatment centers. Geographically, the report examines key regions, including North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
Cancer Gene Therapy Market: The Cancer Gene Therapy Market Report is categorized based on therapy type, end users, and geographical regions. The therapy segment includes gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. End users comprise cancer research institutes, diagnostic centers, and other relevant entities. Geographically, the report analyzes key regions, including North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
Cell Therapy Contract Development and Manufacturing Organization Market: The Cell Therapy Contract Development and Manufacturing Organization Market Report is structured based on services, source, indication, phase, end users, and geography. The services segment includes stem-cell-based, non-stem-cell-based, and other therapies. The source category is divided into clinical and commercial applications. Indications covered in the report include oncology, cardiovascular disease, infectious disease, genetic disorders, neurological disorders, and other conditions. The market is also segmented by phase, encompassing Phase I, Phase II, Phase III, and Phase IV trials. End users include pharmaceutical and biotechnology companies, as well as academic and research institutes. Geographically, the report examines key regions, including North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
About Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries or to access the full report, please contact:
media@mordorintelligence.com
https://www.mordorintelligence.com/